WHO ICTRP trial
Phase 1 Study of CS-7017
JPRN-jRCT2080220936 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-jRCT2080220936 |
|---|---|
| Public title | Phase 1 Study of CS-7017 |
| Scientific title | Phase 1 Study of CS-7017 - Evaluation of Safety and Pharmacokinetics of CS-7017 in Japanese Patients With Solid Cancer |
| Primary sponsor | DAIICHISANKYO Co.,Ltd. |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | 1 |
| Conditions | Solid Cancer not curable with, or not eligible for standard treatment(s) |
| Interventions | investigational material(s) Generic name etc : CS-7017 INN of investigational material : efatutazone Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : CS-7017 administered orally… |
| Registration date | Nov 12, 2009 |
| Target size | 12 |
| Secondary IDs | JapicCTI-090968 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: